Bernstein Liebhard LLP Investigating Diabetes Drug Lawsuits Involving...
The Firm is investigating diabetes drug lawsuits on behalf of patients who took Byetta, Januvia, Victoza or similar medications and were diagnosed with pancreatitis, pancreatic cancer or thyroid...(PRWeb June 16, 2013)Read the full story at http://www.prweb.com/releases/diabetes-drug-lawsuit/pancreatic-cancer/prweb10837515.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 16, 2013 Category: Pharmaceuticals Source Type: news
Diabetes drugs may be linked to pancreatic cancer
Conclusion
This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas.
The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs.
However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging eviden...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news
Diabetes Drug Shows Promise in Parkinson'sDiabetes Drug Shows Promise in Parkinson's
Results of small proof-of-concept trial should spur further interest in funding a larger controlled trial of exenatide in patients with PD. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Testing Diabetes Drug On Parkinson's Disease Patients
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 22, 2013 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news
Weekly Web Review: ricin, gila monsters, and Hitler’s food taster
Caster beans and ricin: At the ToxTalk podcast, Matt Zuckerman, Jen Carey, and Ed Boyer from the University of Massachusetts toxicology program have a level-headed discussion as to whether or not one should panic if an envelope filled with ricin arrives in the mail. I was especially interested to hear about their recent case of a suicidal man who put 30 castor beans through a blender and swallowed the slurry. Tests for urine ricinine were strongly positive. Consistent with TPR‘s long-held belief that the furor about ricin is much ado about (mostly) nothing, the ensuing nausea, vomiting, and abdominal discomfort qui...
Source: The Poison Review - April 27, 2013 Category: Toxicology Authors: Leon Tags: Medical beta blocker poisoning calcium channel blocker toxicity gila monster ricin ToxTalk weekly web review Source Type: news
Report Shows Byetta, Januvia and Other Incretin Mimetic Drugs for Type...
According to the Institute for Safe Medication Practices’ most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to...(PRWeb April 19, 2013)Read the full story at http://www.prweb.com/releases/Byetta-Januvia-cancer/04/prweb10653663.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 23, 2013 Category: Pharmaceuticals Source Type: news
Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. Their findings were published online March 22 in the journal Diabetes.
The researchers, from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida, found that cell mass was increased approximately 40 percent in the pancreases of deceased organ donors who had Type 2 ...
Source: UCLA Newsroom: Health Sciences - March 26, 2013 Category: Universities & Medical Training Source Type: news
Fate of Taspoglutide, a Weekly GLP-1 Agonist, vs ExenatideFate of Taspoglutide, a Weekly GLP-1 Agonist, vs Exenatide
What factors make this investigational GLP-1 receptor agonist unacceptable for use? Diabetes Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Some Diabetes Drugs Linked To Pancreatitis Risk
Diabetes patients who take the newest class of diabetes drugs have double the risk of being hospitalized with acute pancreatitis, researchers from Johns Hopkins University School of Medicine, Baltimore, reported in JAMA Internal Medicine. The authors explained that the new forms of sugar-control medications prescribed to diabetes patients are called GLP-1 (glucagon-like peptide-1). Examples of such drugs include sitagliptin (Januvia) and exenatide (Byetta)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 1, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
The Confusion Over A Pair Of Diabetes Drugs And Pancreatitis
Will yet another study about the risk of pancreatitis spell trouble for some diabetes drugs? The latest instance involves a paper that was published in JAMA Internal Medicine and indicates that Merck’s Januvia and Bristol-Myers Squibb’s Byetta can double the risk of developing pancreatitis. Yes, this is the same issue that, over the past few years, has plagued drugs that increase the GLP-1 hormone. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 1, 2013 Category: Pharmaceuticals Authors: Ed Silverman Source Type: news
Editorial: GLP-1 based agents and acute pancreatitis
Source: BMJ
Area: News
The author of this BMJ editorial discusses a recent study published in JAMA which found that the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide were associated with increased odds of hospitalisation for acute pancreatitis. According to the author, the FDA database carried a signal for acute pancreatitis with exenatide in 2006, a year before the agency alerted clinicians. He states, "Furthermore, all GLP-1 based agents that have been on the market for more than two years have also generated a signal for acute pancreatitis, suggesting a class effect." The regulatory procedures...
Source: NeLM - News - February 28, 2013 Category: Drugs & Pharmacology Source Type: news
Sitagliptin and exenatide associated with an increased risk of acute pancreatitis
Source: JAMA Internal Medicine
Area: News
According to a study published in JAMA Internal Medicine, treatment of type 2 diabetes mellitus with the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalisation for acute pancreatitis.
A large administrative database in the United States was used to collect data for the population-based case-control study - adults with type 2 diabetes mellitus aged 18 to 64 years were identified and 1269 hospitalised cases with acute pancreatitis using a validated algorithm and 1269 control subjects matche...
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news
Newest Diabetes Drugs Linked to Higher Pancreatitis Risk
Patients on Januvia, Byetta twice as likely to develop condition, study says
Source: HealthDay
Related MedlinePlus Pages: Diabetes Medicines, Pancreatitis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 25, 2013 Category: Consumer Health News Source Type: news
Glucagonlike Peptide 1-Based Therapies Associated With Acute Pancreatitis In Study
JAMA Internal Medicine Study Highlights In a study by Sonal Singh, M.D., M.P.H., of The Johns Hopkins University School of Medicine, Baltimore, and colleagues, treatment with the glucagonlike peptide-1 (GLP-1)-based therapies sitagliptin and exenatide were associated with increased odds of hospitalization for acute pancreatitis in adults with type 2 diabetes mellitus. (Online First) The population-based case-control study used a large administrative database of adults with type 2 diabetes. Researchers identified 1,269 hospitalized cases with acute pancreatitis and 1,269 matched controls... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
Horizon Scanning: weekly taspoglutide vs. twice daily exenatide for type 2 diabetes
This study, published in Diabetes Care, compared the efficacy and safety of once-weekly taspoglutide with twice-daily exenatide.
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomised to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 micrograms twice daily (n = 392) in an open-label, multicentre trial. The primary end point was change in HbA1c after 24 weeks.
The authors reported the following results:
. Both doses of taspoglutide reduced HbA1c significantly more than exenatide (...
Source: NeLM - News - February 22, 2013 Category: Drugs & Pharmacology Source Type: news
